Business Wire

GE-RENEWABLE-ENERGY

Share
EU Funding Accelerates GE’s Development of World’s First SF6-free 420 kV Circuit-Breaker

GE Renewable Energy’s Grid Solutions business (NYSE-GE) has been awarded €2.2 million through the European Commission’s LIFE climate action program to help fund the development of a sulfur hexafluoride (SF6 )-free, 420 kiloVolt (kV) 63 kilo Amps (kA) gas-insulated substation (GIS) circuit-breaker.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005296/en/

The new circuit-breaker will rely on GE’s industry-leading “Green Gas for Grid”—or “g3” (pronounced “g- cubed”)—technology, resulting in the same high performance and compact size as a traditional SF6 -insulated circuit-breaker, but with a gas mass having more than a 99% reduced CO₂ equivalent value. Upon completion in 2022, the g3 circuit-breaker is expected to be the first SF6 -free 420 kV gas-insulated substation circuit-breaker in the world.

A circuit-breaker is protective equipment used to cut power in case of a problem on the grid. High-voltage 420-kV circuit-breakers are found at electrical substations on long-distance transmission networks.

Due to its strong insulating and arc-quenching properties, SF6 is widely used in substation equipment with the transmission industry accounting for approximately 80% of the world’s usage. Identified as the world’s most potent greenhouse gas by the 1997 Kyoto Protocol, SF6 is estimated to contribute 23,500 times more emissions than CO₂ if leaked and can remain in the atmosphere for up to 3,200 years.

“Our g3 technology is a game-changing alternative to SF6 for high-voltage equipment and is part of GE’s broader efforts to help the electric transmission and distribution industry reduce its greenhouse gas emissions,” said Vera Silva, Chief Technology Officer at GE’s Grid Solutions.

“Because 420 kV is the highest voltage level used in most European countries, a proven g3 –insulated 420 kV circuit-breaker will demonstrate that g3 technology can be applied to other high-voltage levels, as well as all other gas-insulated substation components, such as disconnectors, earthing switches, voltage transformers,” said Yannick Kieffel, Grid Solutions’ Materials and Eco Design Team Leader and Project Leader for the EU-funded g3 project.

Currently, GE offers the following g3 products: live tank circuit-breakers and gas-insulated substations up to 145 kV, gas-insulated lines up to 420 kV and instrument transformers up to 245 kV.

“This project is a great fit for our recent round of LIFE financial awards due to its potential impact on Europe’s transition to a more sustainable and low-carbon future,” said Angelo Salsi, LIFE Programme Head of Unit at the Executive Agency for Small and Medium-sized Enterprises (EASME). “The LIFE program is one of the most efficient and well known EU funding mechanisms that has supported nature, the environment and climate action for over 25 years. We look forward to the positive ripple effect this project will have across Europe over the next decade and beyond.”

For the full press release on the g3 EU-funded circuit-breaker project LIFE18 CCM/FR/001096 LIFE GRID , click here .

GE’s Grid Solutions

Grid Solutions, a GE Renewable Energy business, serves customers globally with over 17,000 employees in approximately 80 countries. Grid Solutions helps enable utilities and industry to effectively manage electricity from the point of generation to the point of consumption, helping to maximize the reliability, efficiency and resilience of the grid. https://www.gegridsolutions.com/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release

Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr

IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release

Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye